TCT recap: TRYTON, EuroMax, CoreValve, TAVR with CoreValve

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon
 - heart puzzle

In case you missed it, here is our previous coverage from TCT.

In the EUROMAX trial, researchers found that compared to heparin, giving bivalirudin to STEMI patients lowers the risk of death and complications from bleeding, but the strategy faces barriers in the U.S.

The TRYTON trial did meet expectations based on its primary clinical endpoint. The investigators found that using the Tryton stent in patients with large bifurcated coronary lesions led to a higher rate of target vessel failure when compared to patients treated with standard practice and argued that there could be several reasons why the trial was unsuccessful.

In an analysis of the CoreValve device, clinical functionality and quality of life improved in patients with severe aortic stenosis who underwent transcatheter aortic valve replacement (TAVR). A trial of the CoreValve device found it to be safe and effective in TAVR.